Molecular defects of the androgen receptor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 69, Issue 1-6, 1999, Pages 315-322

  McPhaul, Michael J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; RECEPTOR PROTEIN;

AMINO ACID SUBSTITUTION; ANDROGEN INSENSITIVITY SYNDROME; CHEMICAL STRUCTURE; CONFERENCE PAPER; DNA BINDING; DNA SEQUENCE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; LIGAND BINDING; MUSCULAR DYSTROPHY; NONHUMAN; PHENOTYPE; RECEPTOR INTRINSIC ACTIVITY; REPORTER GENE; RNA SPLICING;

AMINO ACID SUBSTITUTION; ANDROGENS; CODON, TERMINATOR; FRAMESHIFT MUTATION; HUMANS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ANDROGEN; TRANSFECTION;

EID: 0032977452     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(99)00050-3     Document Type: Conference Paper

References (42)

1. Wilson J.D., George F.W., Renfree M.B. The endocrine role in mammalian sexual differentiation. Recent Prog. Horm. Res. 50:1995;349-364.
2. Wilson J.D. Role of dihydrotestosterone in androgen action. Prostate Suppl. 6:1996;88-92.
3. Griffin J.E., McPhaul M.J., Russell D.W., Wilson J.D. The androgen resistance syndromes: Steroid 5α-reductase 2 deficiency, testicular feminization, and related disorders. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Bases of Inherited Disease, 7th ed. Chap 95 ed. vol. II:1998;2967-2998 McGraw-Hill, New York.
4. Quigley C.A., De Bellis A., Marschke K.B., El-Awady M.K., Wilson E.M., French F.S. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 16:1995;271-321.
5. Chang C.S., Kokontis J., Liao S.T. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptor. Proc. Natl. Acad. Sci. USA. 85:1988;7211-7215.
6. Lubahn D.B., Joseph D.R., Sar M., Tan J., Higgs H.N., Larson R.E., French F.S., Wilson E.M. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol. Endocrinol. 2:1988;1265-1275.
7. Faber P.W., Kuiper G.G., van Rooij H.C., van der Korput J.A., Brinkmann A.O., Trapman J. The N-terminal domain of the human androgen receptor is encoded by one, large exon. Mol. Cell. Endocrinol. 61:1989;257-262.
8. Tilley W.D., Marcelli M., Wilson J.D., McPhaul M.J. Characterization and expression of a cDNA encoding the human androgen receptor. Proc. Natl. Acad. Sci. USA. 86:1989;327-331.
9. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., et al. The nuclear receptor superfamily: the second decade. Cell. 83:1995;835-839.
10. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
11. La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 352:1991;77-79.
12. Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., Talcott J., Hennekens C.H., Kantoff P.W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA. 94:1997;3320-3323.
13. Stanford J.L., Just J.J., Gibbs M., Wicklund K.G., Neal C.L., Blumenstein B.A., Ostrander E.A. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 57:1997;1194-1198.
14. Ingles S.A., Ross R.K., Yu M.C., Irvine R.A., La Pera G., Haile R.W., Coetzee G.A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. 89:1997;166-170.
15. Lubahn D.B., Brown T.R., Simental J.A., Higgs H.N., Migeon C.J., Wilson E.M., French F.S. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc. Natl. Acad. Sci. USA. 86:1989;9534-9538.
16. Marcelli M., Tilley W.D., Wilson C.M., Griffin J.E., Wilson J.D., McPhaul M.J. Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance. Mol. Endocrinol. 4:1990;1105-1116.
17. Otten A.D., Sanders M.M., McKnight G.S. The MMTV LTR promoter is induced by progesterone and dihydrotestosterone but not by estrogen. Mol. Endo. 2:1988;143-147.
18. Ham J., Thomson A., Needham M., Webb P., Parker M. Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus. Nucleic Acids Res. 16:1988;5263-5276.
19. Cleutjens K.B., van der Korput H.A., van Eekelen C.C., van Rooij H.C., Faber P.W., Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol. Endocrinol. 11:1997;148-161.
20. Kasper S., Rennie P.S., Bruchovsky N., Sheppard P.C., Cheng H., Lin L., Shiu R.P., Snoek R., Matusik R.J. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J. Biol. Chem. 269:1994;31763-31769.
21. Marcelli M., Zoppi S., Wilson C.M., Griffin J.E., McPhaul M.J. Amino acid substitutions in the hormone-binding domain of the human androgen receptor alter the stability of the hormone receptor complex. J. Clin. Invest. 94:1994;1642-1650.
22. McIntosh I., Hamosh A., Dietz H.C. Nonsense mutations and diminished mRNA levels. Nat. Genet. 4:1993;219.
23. Ruiz-Echevarria M.J., Gonzalez C.I., Peltz S.W. Identifying the right stop: determining how the surveillance complex recognizes and degrades an aberrant mRNA. EMBO J. 17:1998;575-589.
24. Zoppi S., Marcelli M., Deslypere J-P., Griffin J.E., Wilson J.D., McPhaul M.J. Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptor-binding positive androgen resistance. Mol. Endocrinol. 6:1992;409-415.
25. Imasaki K., Okabe T., Murakami H., Tanaka Y., Haji M., Takayanagi R., Nawata H. Androgen insensitivity syndrome due to new mutations in the DNA-binding domain of the androgen receptor. Mol. Cell. Endocrinol. 120:1996;15-24.
26. Lobaccaro J.M., Poujol N., Chiche L., Lumbroso S., Brown T.R., Sultan C. Molecular modeling and in vitro investigations of the human androgen receptor DNA-binding domain: application for the study of two mutations. 116. 1996;137-147.
27. McPhaul M.J., Marcelli M., Zoppi S., Wilson C.M., Griffin J.E., Wilson J.D. Mutations in the ligand-binding domain of the androgen receptor gene cluster in two regions of the gene. J. Clin. Invest. 90:1992;2097-2101.
28. Prior L., Bordet S., Trifiro M.A., Mhatre A., Kaufman M., Pinsky L., Wrogeman K., Belsham D.D., Pereira F., Greenberg C., et al. Replacement of arginine 773 by cysteine or histidine in the human androgen receptor causes complete androgen insensitivity with different receptor phenotypes. Am. J. Hum. Genet. 51:1992;143-155.
29. Beitel L.K., Kazemi-Esfarjani P., Kaufman M., Lumbroso R., DiGeorge A.M., Killinger D.W., Trifiro M.A., Pinsky L. Substitution of arginine-839 by cysteine or histidine in the androgen receptor causes different receptor phenotypes in cultured cells and coordinate degrees of clinical androgen resistance. J. Clin. Invest. 94:1994;546-554.
30. Kazemi-Esfarjani P., Beitel L.K., Trifiro M.A., Kaufman M., Rennie P., Sheppard P., Matusik R., Pinsky L. Substitution of valine-865 by methionine or leucine in the human androgen receptor causes complete or partial androgen insensitivity, respectively with distinct androgen receptor phenotypes. Mol. Endocrinol. 7:1993;37-46.
31. Ris-Stalpers C., Trifiro M.A., Kuiper G.G., Jenster G., Romalo G., Sai T., van Rooij H.C., Kaufman M., Rosenfield R.L., Liao S., et al. Substitution of aspartic acid-686 by histidine or asparagine in the human androgen receptor leads to a functionally inactive protein with altered hormone-binding characteristics. Mol. Endocrinol. 5:1991;1562-1569.
32. Grino P.B., Isidro-Gutierrez R.F., Griffin J.E., Wilson J.D. Androgen resistance associated with a qualitative abnormality of the androgen receptor and responsive to high dose androgen therapy. J. Clin. Endo. Metab. 68:1989;578-584.
33. Tincello D.G., Saunders P.T., Hodgins M.B., Simpson N.B., Edwards C.R., Hargreaves T.B., Wu F.C. Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone in patients with partial androgen insensitivity syndrome. Clin. Endocrinol. 46:1997;497-506.
34. Yong E.L., Ng S.C., Roy A.C., Yun G., Ratnam S.S. Pregnancy after hormonal correction of severe spermatogenic defect due to mutation in androgen receptor gene. Lancet. 344:1994;826-827.
35. McPhaul M.J., Deslypere J-P., Allman D.R., Gerard R.D. The adenovirus-mediated delivery of a reporter gene permits the assessment of androgen receptor function in genital skin fibroblast cultures. J. Biol. Chem. 268:1993;26063-26066.
36. McPhaul M.J., Schweikert H-U., Allman D.R. Assessment of androgen receptor function in genital skin fibroblasts using a recombinant adenovirus to deliver an androgen-responsive reporter gene. J. Clin. Endo. Metab. 82:1997;1944-1948.
37. Butler R., Leigh P.N., McPhaul M.J., Gallo J.M. Truncated forms of the androgen receptor are associated with polyglutamine expansion in X-linked spinal and bulbar muscular atrophy. Hum. Mol. Genet. 7:1998;121-127.
38. Merry D.E., Kobayashi Y., Bailey C.K., Taye A.A., Fischbeck K.H. Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy. Human Molecular Genetics. 7:1998;693-701.
39. Abdullah A.A.R., Trifiro M.A., Panetraymond V., Alvarado C., Detourreil S., Frankel D., Schipper H.M., Pinsky L. Spinobulbar muscular atrophy-polyglutamine-expanded androgen receptor is proteolytically resistant in vitro and processed abnormally in transfected cells. Hum. Mol. Genet. 7:1998;379-394.
40. Tilley W.D., Buchanan G., Hickey T.E., Bentel J.M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 2:1996;277-285.
41. Fenton M.A., Shuster T.D., Fertig A.M., Taplin M.E., Kolvenbag G., Bubley G.J., Balk S.P. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. 3:1997;1383-1388.
42. McPhaul M.J. The androgen receptor and prostate cancer. Pasqualini J.R., Katzenellenbogen B.S. Hormone-Dependent Cancer. 1996;307-321 Marcel Dekker, New York.